Pegaspargase
- Generic Name
- Pegaspargase
- Brand Names
- Oncaspar
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 130167-69-0
- Unique Ingredient Identifier
- 7D96IR0PPM
- Background
Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synt...
- Indication
Pegaspargase is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with 1) first-line acute lymphoblastic leukemia or 2) acute lymphoblastic leukemia and hypersensitivity to asparaginase.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 15
- Registration Number
- NCT00882206
- Locations
- 🇺🇸
University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota, United States
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- B-cell Childhood Acute Lymphoblastic LeukemiaRecurrent Adult Lymphoblastic LymphomaT-cell Adult Acute Lymphoblastic LeukemiaT-cell Childhood Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaB-cell Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Lymphoblastic Lymphoma
- Interventions
- Drug: L-asparaginaseDrug: doxorubicin hydrochlorideDrug: therapeutic hydrocortisoneDrug: vincristine sulfateDrug: cytarabineDrug: prednisoneDrug: bortezomibDrug: pegaspargaseDrug: methotrexateDrug: etoposide phosphateDrug: cyclophosphamideBiological: filgrastimDrug: leucovorin calciumOther: laboratory biomarker analysisDrug: High Dose MTX
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 148
- Registration Number
- NCT00873093
- Locations
- 🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)
- Conditions
- Interventions
- Drug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Doxorubicin HydrochlorideOther: Laboratory Biomarker AnalysisDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseDrug: ThioguanineDrug: Vincristine SulfateDrug: PrednisoneRadiation: Prophylactic Cranial Irradiation
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 104
- Registration Number
- NCT00866307
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States
🇺🇸Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT00866749
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: AsparaginaseDrug: CyclophosphamideDrug: CytarabineDrug: DasatinibDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: EtoposideBiological: FilgrastimDrug: Hydrocortisone Sodium SuccinateDrug: IfosfamideOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: MethylprednisoloneDrug: PegaspargaseDrug: PrednisoneRadiation: Radiation TherapyDrug: Vincristine Sulfate
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 63
- Registration Number
- NCT00720109
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: Calaspargase Pegol-mknlDrug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Doxorubicin HydrochlorideOther: Laboratory Biomarker AnalysisDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseOther: Pharmacological StudyDrug: PrednisoneRadiation: Radiation TherapyDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 166
- Registration Number
- NCT00671034
- Locations
- 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸University of Connecticut, Farmington, Connecticut, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 318
- Registration Number
- NCT00558519
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: AsparaginaseProcedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyDrug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DexamethasoneProcedure: EchocardiographyDrug: EtoposideBiological: FilgrastimOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: LestaurtinibDrug: MercaptopurineDrug: MethotrexateDrug: MethylprednisoloneProcedure: Multigated Acquisition ScanDrug: PegaspargaseOther: Pharmacological StudyDrug: PrednisoneDrug: Therapeutic HydrocortisoneDrug: Vincristine Sulfate
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 218
- Registration Number
- NCT00557193
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
- Conditions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Dutch Childhood Oncology Group
- Target Recruit Count
- 445
- Registration Number
- NCT00550992
- Locations
- 🇨🇿
University Hospital Motol, Prague, Czechia
🇫🇷CHR Hotel Dieu, Nantes, France
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 160
- Registration Number
- NCT00501826
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.